Trial · NCT05115110
Registered outcomes34
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 34
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1 - Percentage of participants with adverse events (AEs) | Up to 4.5 years | |
| Primary | Part 1 - Incidence of relevant echocardiographic parameter z scores > 2 | Up to 4.5 years | |
| Primary | Part 1 - Serum concentration of RO7204239 | Through Week 96 | |
| Primary | Part 1 - Time to maximum serum concentration (Cmax) of RO7204239 | Through Week 96 | |
| Primary | Part 1 - Area under the curve (AUC) of RO7204239 | Through Week 96 | |
| Primary | Part 1 - Trough concentration (Ctrough) of RO7204239 | Through Week 96 | |
| Primary | Part 1 - Plasma concentration of risdiplam | Week 21 | |
| Primary | Part 1 - Plasma concentration of risdiplam metabolite (M1) | Week 21 | |
| Primary | Part 1 - Cmax of risdiplam | Week 21 | |
| Primary | Part 1 - AUC of risdiplam | Week 21 | |
| Primary | Part 1 - Ctrough of risdiplam | Week 21 | |
| Primary | Part 1 - Incidence of anti-drug antibodies (ADAs) | Through Week 96 | |
| Primary | Part 1 - Change from baseline in serum concentration of total myostatin | Through Week 85 | |
| Primary | Part 1 - Change from baseline in serum concentration of free latent myostatin | Through Week 85 | |
| Primary | Part 1 - Change from baseline in serum concentration of mature myostatin | Through Week 85 | |
| Primary | Part 1 - Percent change from baseline in the contractile area of skeletal muscle in the dominant thigh muscles as assessed by magnetic resonance imaging (MRI) in participants aged at least 5 years | Week 24 of combination treatment | |
| Primary | Part 1 - Percent change from baseline in the contractile area of skeletal muscle in the dominant calf muscles as assessed by MRI in participants aged at least 5 years | Week 24 of combination treatment | |
| Primary | Part 2 - Change from baseline in Revised Hammersmith Scale (RHS) total score | Week 72 of combination treatment (study Week 80) | |
| Secondary | Part 2 - Change from baseline in Motor Function Measure (MFM) Domain 1 + Domain 2 (D1 + D2) score | Week 72 of combination treatment (study Week 80) | |
| Secondary | Part 2 - Change from baseline in MFM-32 total score | Week 72 of combination treatment (study Week 80) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05115110/registered